e-learning
resources
Glasgow 2004
Sunday 05.09.2004
Pulmonary hypertension
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Intrapulmonary shunt effect induces by nicardipine but not by urapidil in pulmonary hypertension
V. Doyen, P. Bulpa, J. Jamart, E. Installé, P. Evrard (Yvoir, Belgium)
Source:
Annual Congress 2004 - Pulmonary hypertension
Session:
Pulmonary hypertension
Session type:
Oral Presentation
Number:
1299
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Doyen, P. Bulpa, J. Jamart, E. Installé, P. Evrard (Yvoir, Belgium). Intrapulmonary shunt effect induces by nicardipine but not by urapidil in pulmonary hypertension. Eur Respir J 2004; 24: Suppl. 48, 1299
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Haemodynamics during vasodilator test comparing urapidil and nicardipine to NO in pulmonary arterial hypertension
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Effects of suramin on cardiopulmonary capacity and pulmonary venous contraction in pulmonary arterial hypertension
Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle
Year: 2018
Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Sildenafil enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 24s
Year: 2002
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 339-343
Year: 2002
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 1354-1360
Year: 2009
Effects of nebulised iloprost on pulmonary function and oxygenation in patients with severe pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 370s
Year: 2002
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016
Intravenous iloprost for pulmonary arterial hypertension: still waiting for evidence
Source: Eur Respir J 2009; 34: 7-9
Year: 2009
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Source: Eur Respir J 2006; 28: 1195-1203
Year: 2006
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
Long-term effects of bosentan on the heart and pulmonary hemodynamics in pulmonary arterial hypertension, a comparison study with epoprostenol
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
Long-term outcome with intravenous iloprost in pulmonary arterial hypertension
Source: Eur Respir J 2009; 34: 132-137
Year: 2009
Inhaled iloprost improves hemodynamics at exercise in primary and secondary precapillary pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002
Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary arterial hypertension
Year: 2009
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1483-1485
Year: 2010
Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
Source: Eur Respir J 2001; 17: 14-19
Year: 2001
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept